Anti-Microbial Savior BioteQ Co., Ltd. (TPEX:6864)
Taiwan · Delayed Price · Currency is TWD 47.65
-0.25 (-0.52%)
Jun 18, 2026, 2:58 PM CST
TPEX:6864 Revenue
In the year 2024, Anti-Microbial Savior BioteQ had annual revenue of 612.00K TWD, down -15.93%. Anti-Microbial Savior BioteQ had revenue of 267.00K in the half year ending December 31, 2024, with 203.41% growth.
Revenue
612.00K
Revenue Growth
-15.93%
P/S Ratio
2,533.14
Revenue / Employee
n/a
Employees
n/a
Market Cap
1.55B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 612.00K | -116.00K | -15.93% |
| Dec 31, 2023 | 728.00K | -1.97M | -73.01% |
| Dec 31, 2022 | 2.70M | 2.61M | 2,964.77% |
| Dec 31, 2021 | 88.00K | 15.00K | 20.55% |
| Dec 31, 2020 | 73.00K | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Synbio Tech | 1.02B |
| GenMont Biotech Incorporation | 401.23M |
| Abnova (Taiwan) | 348.71M |
| NeoCore Technology | 235.54M |
| 3D Global Biotech | 206.74M |
| TaiRx | 27.88M |
| Great Novel Therapeutics Biotech & Medicals | 1.21M |